Pfizer faces Neurontin class action in Canada; Barron's tags Mylan for 20% share growth;

  @FiercePharma: One-fourth of new scrips go unfilled. Article | Follow @FiercePharma

> Pfizer faces a national class-action lawsuit in most of Canada over claims it failed to warn consumers about the risks of its Neurontin epilepsy drug. Report

> Shares in generic drugmaker Mylan could rise a further 20 percent over the next year, as more prescriptions outside of the U.S. are filled by generics, Barron's reported on Sunday. Report

> Nearly six months after a New Jersey judge dismissed a lawsuit filed by Biovail against the SAC hedge fund, that fund has returned the favor by suing the Canadian pharmaceutical company. Report

> Barclays Capital raised its target price for Teva Pharmaceutical Industries to $69 from $66, while reiterating its "Overweight" recommendation. Report

> Evidence is mounting that placebo treatments have an actual biological effect in the body, a review of recent research found. Report

> Roche and Boehringer Ingelheim's Indonesian operations inked a deal to share licensing and manufacturing for products at Boehringer's plant in West Java. Report

Biotech News

 @FierceBiotech: Basilea suffers setback as EU won't back its lead drug ceftobiprole. Article  | Follow @FierceBiotech

 @JohnCFierce: Shire plans to undercut Cerezyme by 15% on price. Could a price war be shaping up? That's $30K less per patient. Article | Follow @JohnCFierce 

> Anthera has no sales or profit, but the company is hoping to raise almost $70 million in an IPO offering this week. Report

> The U.K.'s ReNeuron Group has raised £4.7 million ($7.3 million), before expenses, from existing and new institutional investors. Article

> A data monitoring committee has recommended the continued study of BioSante's LibiGel as a treatment for sexual dysfunction in women following the review of positive safety data from a Phase III clinical trial. Story

> Was Rigel's $1.2B RA deal over-hyped? Item

> Biogen Idec CEO James Mullen may be ready to walk out the door, but the big biotech doesn't have a replacement lined up yet. Report

> The FDA has approved Novartis' Menveo vaccine for use in 11-55 year olds to help protect against meningitis and sepsis caused by four common vaccine-preventable serogroups. Story

Biotech IT News

> Potentially valid drugs are sometimes denied FDA approval because flawed clinical data undermines efficacy and safety findings, says Health Decisions. Report

> Greg Nelson ponders whether clinical informatics provides a competitive advantage for drug developers. Article

> The pharmaceutical industry has entered the elite realm of high-volume, high-value, high-sensitivity data generators prized by cyber-attackers. Story

> Service provider Quintiles is taking a marketing tack to improve patient-recruitment capabilities. Report

> ISI is attempting to kill two regulatory automation birds with one stone: ISIRegTracker version 4.2, part of its Regulatory Information Management system. Story

And Finally... Is happiness the best medicine? A new report suggests it's good for the heart at least. Report